Clinically approved HDAC IC50 values against all HDAC gene products [22]
HDAC isozyme | Vorinostat, hydroxamate (nmol/L) | Tucidinostat, anilide (nmol/L) | Romidepsin, thiol (nmol/L) | Panobinostat, hydroxamate (nmol/L) | Belinostat, hydroxamate (nmol/L) |
1 | 60 | 100 | 1 | 3 | 26 |
2 | 42 | 200 | 1 | 2 | 22 |
3 | 36 | 100 | 1 | 2 | 19 |
4 | 20 | > 10,000 | 647 | 1 | 15 |
5 | 36 | > 10,000 | > 1,000 | 1 | 25 |
6 | 29 | > 10,000 | 226 | 1 | 10 |
7 | 129 | > 10,000 | > 1,000 | 2 | 51 |
8 | 173 | 700 | > 1,000 | 22 | 22 |
9 | 49 | > 10,000 | > 1,000 | 1 | 24 |
10 | 60 | 100 | 1 | 31 | 59 |
11 | 31 | 400 | 0.3 | 4 | 27 |
DIA, EDdA, and PTG: Conceptualization. DIA, NHP, and LSH: Investigation, Data collection. DIA: Writing—original draft. DIA, EDdA, OHK, RM, NHP, LSH, and PTG: Writing—review & editing. DIA, EDdA, OHK, RM, and PTG: Validation. DIA and PTG: Supervision. All authors read and approved the submitted version.
The authors declare that they have no conflicts of interest.
Not applicable.
Not applicable.
Not applicable.
Not applicable.
Not applicable.
© The Author(s) 2023.